ZnT8 Antibodies

Zinc Transporter 8 Autoantibodies

- ZnT8 antibody distinguishes type 1 and type 2 diabetes mellitus.

- ZnT8 antibody identifies relatives of diabetic patients at most risk for developing diabetes.

- ZnT8 antibody predicts the future need for insulin treatment in adult-onset diabetic patients.

- ZnT8 antibody predicts the future development of diabetes mellitus in women with gestational diabetes.

Detects zinc transporter 8 autoantibodies (ZnT8), an autoimmune diabetes marker that is instrumental in the diagnosis of new-onset type 1 diabetes

-------------------------

Islet cell autoantibodies have been known to be associated with type 1 diabetes mellitus since the 1970s. Since 1988, several autoantigens against which islet antibodies are directed have been identified. These include the insulinoma-associated protein 2 (IA-2), glutamic acid decarboxylase 65 (GAD65), insulin, and, most recently, the zinc transporter ZnT8. Only 4% to 7% of patients with type 1 diabetes are autoantibody negative, fewer than 10% have only 1 marker, and around 70% have 3 or 4 markers. These findings have been confirmed in multiple specialty laboratories internationally.

One or more of these autoantibodies are detected in 93% to 96% of patients with type 1 diabetes, both adults and children. These antibodies are also detectable in relatives of type 1 diabetic patients at risk for developing diabetes, before clinical onset. Because of symptom-onset in adulthood, societal obesity, and initial insulin-independence, some patients with type 1 diabetes are initially diagnosed as having type 2 diabetes,. These patients with either "latent autoimmune diabetes in adulthood" or type 1 diabetes mellitus, may be distinguished from those patients with type 2 diabetes by detection of 1 or more islet autoantibodies, including ZnT8 antibody.(2-5) Patients with gestational diabetes can also be stratified for future diabetes risk by detection of 1 or more islet autoantibodies (including ZnT8 antibody).